Page last updated: 2024-08-26

sr141716 and Weight Loss

sr141716 has been researched along with Weight Loss in 98 studies

Research

Studies (98)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.02)	18.2507
2000's	66 (67.35)	29.6817
2010's	30 (30.61)	24.3611
2020's	1 (1.02)	2.80

Authors

Authors	Studies
Chang, CP; Chao, YS; Chiu, HH; Chu, CM; Chung, WL; Hsieh, WP; Hung, MS; Kuo, CW; Lin, Y; Shia, KS; Song, JS; Tai, CL; Tseng, SL; Tung, YS; Wu, CH	1
Blumen, T; Brake, R; Cohen, Y; Ferreira, S; Kolodziej, A; Morningstar, M	1
Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Dawson, AJ; Elshewehy, AMM; Kilpatrick, ES; Sathyapalan, T	1
Han, JH; Kim, KW; Kim, W; Park, JY; Rho, JG; Seong, JK; Shin, H; Son, DH; Yoon, SH	1
Asare-Bediako, I; Bergman, RN; Clegg, DJ; Iyer, MS; Kabir, M; Kim, SP; Kolka, CM; Paszkiewicz, RL; Richey, JM; Stefanovski, D; Woolcott, OO; Wu, Q	1
Berghold, A; Horvath, K; Jeitler, K; Semlitsch, T; Siebenhofer, A; Siering, U	1
Carlsson, B; Hansson, GI; Hjorth, S; Karlsson, C; Karpefors, M	1
Chang, CP; Chao, YS; Chen, PH; Hsiao, WC; Hung, MS; Lin, Y; Shia, KS; Wang, YT; Wu, CH; Yeh, YN	1
Berghold, A; Horvath, K; Jeitler, K; Meschik, J; Posch, N; Semlitsch, T; Siebenhofer, A	1
Antoniou, K; Delis, F; Gueye, AB; Laviolette, SR; Le Foll, B; Loureiro, M; Makriyannis, A; Poulia, N; Pryslawsky, Y; Trigo, JM; Vemuri, K	1
Atkin, SL; Coady, AM; Javed, Z; Kilpatrick, ES; Sathyapalan, T	1
Piomelli, D	1
Chaput, JP; Tremblay, A	1
Pagotto, U; Pasquali, R; Vanuzzo, D; Vicennati, V	1
Harrison, SA; Kashi, MR; Torres, DM	1
Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T	2
Idelevich, E; Kirch, W; Schindler, C	1
Galzin, AM; Guillot, E; Lacombe, A; Lefèvre, AL; Magnan, C; Migrenne, S; Pruniaux, MP	1
Faludi, G; Halmy, L; Purebl, G; Rihmer, Z	1
Choussein, S; Daskalopoulou, SS; Frangos, CC; Makri, AA; Petridou, ET	1
Berghold, A; Horvath, K; Jeitler, K; Matyas, E; Pignitter, N; Siebenhofer, A; Siering, U; Stich, AK	1
Ducluzeau, PH; Flamment, M; Gueguen, N; Malthièry, Y; Simard, G; Wetterwald, C	1
Burch, J; Glanville, J; McKenna, C; Norman, G; Palmer, S; Sculpher, M; Woolacott, N	1
Derdemezis, CS; Elisaf, M; Florentin, M; Liberopoulos, EN; Tellis, CC; Tselepis, A	1
Cohen, SB; DiPetrillo, K; Xu, L; Zhang, Y	1
Axel, AM; Hansen, G; Hansen, HH; Larsen, PJ; Mikkelsen, JD; Raben, A; Tang-Christensen, M	1
Ballantyne, CM; Mansoori, A; Perrard, JL; Perrard, XD; Smith, CW; Wang, Q; Wu, H	1
Atkin, SL; Dawson, AJ; Kilpatrick, ES; Mellor, DD; Sathyapalan, T	1
Madsbad, S	1
Boustany-Kari, CM; Gibbons, CP; Jackson, VM; Swick, AG	1
Bennetzen, MF	1
Botha, AJ; Crook, MA; Dar, A; McMahon, Z; Oben, J; Pendleton, S; Wierzbicki, AS	1
Brown, MW; Deanfield, JE; Després, JP; Job, B; Kastelein, JJ; Nissen, SE; O'Leary, DH; Reuwer, AQ; Visseren, FL; Zabbatino, SM; Zhou, R	1
Bajzer, M; Cota, D; Foster, MT; Haas, MK; Krawczewski-Carhuatanta, KA; Magrisso, IJ; Obici, S; Olivieri, M; Pfluger, PT; Tschöp, MH	1
Abu-Lebdeh, H; Jensen, M; Klein, S; Mundi, M; Smith, SR; Toledo, FG; Triay, J	1
Clapham, JC; Gamo, Y; Mitchell, SE; Morgan, DG; Sinclair, R; Speakman, JR; Zhang, LN	1
Abrams, K; Ara, R; Cooper, N; Davies, MJ; Dunkley, A; Gray, LJ; Khunti, K; Sutton, A; Warren, FC	1
Backhouse, K; Bell, JD; Frost, GS; Robertson, MD; Russell-Jones, D; Sarac, I; Shojaee-Moradie, F; Stolinski, M; Thomas, EL; Umpleby, AM; Wright, J	1
Lockie, SH; Oldfield, BJ; Stefanidis, A; Verty, AN	1
Chen, D; Liu, X; Shi, Y; Zhang, W	1
Bunce, S; Heppenstall, C; Smith, JC	1
Bergholm, R; Hakkarainen, A; Kotronen, A; Lundbom, J; Lundbom, N; Rissanen, A; Santos, A; Sevastianova, K; Tiikkainen, M; Urjansson, M; Yki-Järvinen, H	1
Businco, F; Dessi, C; Fadda, P; Fattore, L; Fratta, W; Goldberg, SR; Pigliacampo, B; Satta, V; Scherma, M	1
Gasteyger, C; Golay, A; Hanotin, C; Pataky, Z; Rissanen, A; Ziegler, O	1
Avraham, Y; Ben-Shushan, D; Berry, EM; Breuer, A; Fink, N; Katz, V; Okon, A; Zolotarev, O	1
Einecke, D	1
Aumiller, J	1
Conti, CR	1
Böcking, W; Bramlage, P; Kirch, W	1
Kvasnicka, T	1
Wadman, M	2
Després, JP; Golay, A; Sjöström, L	1
Yanovski, SZ	1
Kordella, T	1
Anggadiredja, K; Shoyama, Y; Tanaka, H; Watanabe, S; Yamaguchi, T; Yamamoto, T	1
Astrup, AV; Breum, L; Bruun, JM; Svendsen, OL; Toubro, S	1
Letonturier, P	1
Aronne, LJ; Devin, J; Heshmati, HM; Pi-Sunyer, FX; Rosenstock, J	1
Gadde, KM	1
Majumdar, S; Padwal, R	1
Hamann, A	1
Halpern, A; Mancini, MC	1
Allison, DB; Gadde, KM	1
Cannon, E; Lundquist, LM; Sirimaturos, M	1
André, C; Curioni, C	1
Fujioka, K	1
Majumdar, SR; Padwal, RS	1
Bennett, AJ; Kendall, DA; O'Sullivan, SE; Randall, MD	1
Roberfroid, D	1
Henzen, C	1
Scheen, AJ; Van Gaal, LF	1
Saavedra, LE	1
Gargallo, M; Isabel Millán, A; Moreno, B; Rubio, MA	1
Watson, KE	1
Pfeiffer, AF	1
Käser, L; Kolyvanos, NU; Suter, PM; Vetter, W	1
Astrup, A; Bartels, EM; Bliddal, H; Christensen, R; Kristensen, PK	1
Boekholdt, SM; Jukema, JW; Peters, RJ	1
Cohen, AF; Dubois, EA; Pijl, H; van Bronswijk, H	1
McCall, AL	1
Després, JP; Mancia, G; Pi-Sunyer, X; Ruilope, LM; Scheen, A; Van Gaal, L; Zanchetti, A	1
Kaila, B; Raman, M	1
Nau, JY	1
Nilsson, PM	1
Forslund, T; Hjemdahl, P; Raaschou, P; Wettermark, B	1
Elvert, R; Haschke, G; Herling, AW; Kilp, S; Kramer, W	1
Aronsen, L	1
Berry, C; Bourassa, MG	1
Hanotin, C; Rissanen, AM; Rössner, S; Scheen, AJ; Van Gaal, LF; Ziegler, O	1
Aronne, LJ; Isoldi, KK	1
Agabio, R; Colombo, G; Diaz, G; Gessa, GL; Lobina, C; Reali, R	1

Reviews

32 review(s) available for sr141716 and Weight Loss

Article	Year
Long-term effects of weight-reducing drugs in hypertensive patients. The Cochrane database of systematic reviews, 2013, Mar-28, Issue:3 Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Diet, Reducing; Female; Humans; Hypertension; Lactones; Male; Middle Aged; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Safety-Based Drug Withdrawals; Time; Weight Loss	2013
Long-term effects of weight-reducing drugs in people with hypertension. The Cochrane database of systematic reviews, 2016, Mar-02, Volume: 3 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cyclobutanes; Diet, Reducing; Female; Fructose; Humans; Hypertension; Lactones; Male; Middle Aged; Orlistat; Phentermine; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Safety-Based Drug Withdrawals; Time; Topiramate; Weight Loss	2016
Current and emerging therapies in nonalcoholic fatty liver disease. Seminars in liver disease, 2008, Volume: 28, Issue:4 Topics: Animals; Antioxidants; Bariatric Surgery; Body Mass Index; Cannabinoids; Cholagogues and Choleretics; Comorbidity; Fatty Liver; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Lactones; Life Style; Metformin; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Treatment Outcome; Ursodeoxycholic Acid; Weight Loss	2008
Current pharmacotherapeutic concepts for the treatment of obesity in adults. Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:1 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Combined Modality Therapy; Cyclobutanes; Enzyme Inhibitors; Humans; Lactones; Lipase; Obesity; Orlistat; Piperidines; Prevalence; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Reduction Behavior; Treatment Outcome; Weight Loss	2009
[Association of obesity and depression]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2008, Volume: 10, Issue:4 Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Appetite Regulation; Bipolar Disorder; Circadian Rhythm; Cyclobutanes; Depression; Depressive Disorder, Major; Dietary Carbohydrates; Energy Intake; Ghrelin; Humans; Hypothalamo-Hypophyseal System; Insulin Resistance; Leptin; Obesity; Piperidines; Pituitary-Adrenal System; Pyrazoles; Rimonabant; Seasonal Affective Disorder; Sleep Wake Disorders; Surveys and Questionnaires; Weight Gain; Weight Loss	2008
Effect of antiobesity medications in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:7 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Body Weight; Cyclobutanes; Diabetes Mellitus, Type 2; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome; Weight Loss; Young Adult	2009
Long-term effects of weight-reducing drugs in hypertensive patients. The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3 Topics: Adult; Anti-Obesity Agents; Blood Pressure; Cyclobutanes; Female; Humans; Hypertension; Lactones; Male; Middle Aged; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time; Weight Loss	2009
Rimonabant for the treatment of overweight and obese people. Health technology assessment (Winchester, England), 2009, Volume: 13 Suppl 3 Topics: Anti-Obesity Agents; Cost-Benefit Analysis; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2009
Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options. Danish medical bulletin, 2011, Volume: 58, Issue:4 Topics: Adiponectin; Adipose Tissue; Animals; Body Mass Index; Body Weight; C-Reactive Protein; Cannabinoid Receptor Modulators; Case-Control Studies; Endocannabinoids; Fatty Acids, Nonesterified; Feeding Behavior; Female; Genetic Variation; Humans; Inflammation; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Wistar; Reference Values; Rimonabant; Risk Factors; Weight Loss	2011
A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2012, Volume: 13, Issue:6 Topics: Anti-Obesity Agents; Body Mass Index; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome; Weight Loss	2012
[Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation]. Casopis lekaru ceskych, 2005, Volume: 144, Issue:2 Topics: Arachidonic Acids; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Endocannabinoids; Humans; Metabolic Syndrome; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rimonabant; Smoking; Smoking Cessation; Weight Loss	2005
[Drug treatment of obesity]. Ugeskrift for laeger, 2006, Jan-09, Volume: 168, Issue:2 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diethylpropion; Enzyme Inhibitors; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time Factors; Weight Loss	2006
Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction. Current drug targets. Cardiovascular & haematological disorders, 2005, Volume: 5, Issue:6 Topics: Cannabinoid Receptor Antagonists; Humans; Models, Biological; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2005
[Pharmacotherapy in the treatment of obesity]. MMW Fortschritte der Medizin, 2006, Mar-02, Volume: 148, Issue:9 Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Cyclobutanes; Enzyme Inhibitors; Exercise; Humans; Lactones; Lipase; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Time Factors; Weight Loss	2006
Pharmacological treatment of obesity. Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:2 Topics: Amphetamines; Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Cyclobutanes; Energy Metabolism; Homeostasis; Humans; Lactones; Mazindol; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2006
Pharmacologic treatment for obesity. Options for today...and tomorrow. Advance for nurse practitioners, 2006, Volume: 14, Issue:8 Topics: Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Drug Therapy, Combination; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2006
Rimonabant for overweight or obesity. The Cochrane database of systematic reviews, 2006, Oct-18, Issue:4 Topics: Adult; Anti-Obesity Agents; Diet, Reducing; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Weight Loss	2006
Metabolic syndrome treatment strategies. Pharmacotherapy, 2006, Volume: 26, Issue:12 Pt 2 Topics: Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Exercise; Humans; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Weight Loss	2006
Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet (London, England), 2007, Jan-06, Volume: 369, Issue:9555 Topics: Anti-Obesity Agents; Blood Pressure; Cholesterol, HDL; Cyclobutanes; Half-Life; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Weight Loss	2007
[Internal medicine--update 2006]. Praxis, 2007, Mar-14, Volume: 96, Issue:11 Topics: Adrenal Gland Neoplasms; Bradykinin; Carotid Stenosis; Clinical Trials as Topic; Contrast Media; Endarterectomy, Carotid; Esophageal and Gastric Varices; Female; Heart Failure; Humans; Hyperglycemia; Hypertension; Hyperthyroidism; Internal Medicine; Male; Middle Aged; Osteitis Deformans; Piperidines; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Renal Insufficiency; Rimonabant; Risk Factors; Stents; Stethoscopes; Weight Loss	2007
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Revue medicale de Liege, 2007, Volume: 62, Issue:2 Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss	2007
Less weight or more hype with rimonabant? Drug and therapeutics bulletin, 2007, Volume: 45, Issue:6 Topics: Anti-Obesity Agents; Cardiovascular Diseases; Drug Costs; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Treatment Outcome; Weight Loss	2007
Endocannabinoid system and cardiometabolic risk. Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:5 Topics: Abdominal Fat; Adipokines; Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Endocannabinoids; Humans; Insulin Resistance; Lipids; Obesity; Overweight; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss	2007
Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public health nutrition, 2007, Volume: 10, Issue:10A Topics: Anti-Obesity Agents; Cyclobutanes; Humans; Lactones; Life Style; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Safety; Treatment Outcome; Weight Loss	2007
Novel therapies for cardiometabolic risk reduction and implications for clinical practice. Reviews in cardiovascular medicine, 2007, Volume: 8 Suppl 4 Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Dyslipidemias; Exercise; Humans; Insulin Resistance; Life Style; Lipids; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Assessment; Risk Factors; Treatment Outcome; Weight Loss	2007
Adipose tissue and diabetes therapy: do we hit the target? Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2007, Volume: 39, Issue:10 Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Drug Delivery Systems; Humans; Hypoglycemic Agents; Insulin; Metformin; Models, Biological; Piperidines; Pyrazoles; Rimonabant; Sulfonylurea Compounds; Thiazolidinediones; Weight Loss	2007
[Obesity in adults]. Praxis, 2007, Oct-17, Volume: 96, Issue:42 Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Body Mass Index; Cyclobutanes; Diagnosis, Differential; Enzyme Inhibitors; Humans; Lactones; Male; Middle Aged; Obesity; Obesity, Morbid; Orlistat; Overweight; Piperidines; Prognosis; Pyrazoles; Rimonabant; Time Factors; Weight Loss	2007
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet (London, England), 2007, Nov-17, Volume: 370, Issue:9600 Topics: Anti-Obesity Agents; Anxiety Disorders; Depression; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Weight Loss	2007
[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant]. Nederlands tijdschrift voor geneeskunde, 2007, Nov-24, Volume: 151, Issue:47 Topics: Cardiovascular Diseases; Depression; Diet, Reducing; Humans; Lipids; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss	2007
Obesity: a review of pathogenesis and management strategies. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2008, Volume: 22, Issue:1 Topics: Anti-Obesity Agents; Bariatric Surgery; Behavior Therapy; Caloric Restriction; Cyclobutanes; Dietary Carbohydrates; Dietary Fats; Exercise; Humans; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2008
Is weight loss beneficial for reduction of morbidity and mortality? What is the controversy about? Diabetes care, 2008, Volume: 31 Suppl 2 Topics: Bariatric Surgery; Cannabinoids; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Life Style; Multicenter Studies as Topic; Obesity; Piperidines; Power, Psychological; Pyrazoles; Rimonabant; Self Concept; Weight Loss	2008
The challenge of treating obesity: the endocannabinoid system as a potential target. Journal of the American Dietetic Association, 2008, Volume: 108, Issue:5 Topics: Appetite Regulation; Blood Glucose; Cannabinoid Receptor Modulators; Drug Approval; Endocannabinoids; Energy Metabolism; Humans; Lipid Metabolism; Obesity; Piperidines; Pyrazoles; Rimonabant; United States; United States Food and Drug Administration; Weight Loss	2008

Trials

16 trial(s) available for sr141716 and Weight Loss

Article	Year
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. BMC endocrine disorders, 2017, Jul-14, Volume: 17, Issue:1 Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Liver Diseases; Metformin; Obesity; Orlistat; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prognosis; Pyrazoles; Receptor, Cannabinoid, CB1; Retrospective Studies; Rimonabant; Thiazolidinediones; Weight Loss	2017
Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome. Clinical endocrinology, 2017, Volume: 86, Issue:3 Topics: Biomarkers; Cannabinoid Receptor Antagonists; Cytokines; Female; Humans; Hyperandrogenism; Inflammation; Interleukin-8; Metformin; Obesity; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Vascular Endothelial Growth Factor A; Weight Loss	2017
Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). Clinical endocrinology, 2009, Volume: 70, Issue:1 Topics: Adult; Androgens; Female; Humans; Insulin Resistance; Metformin; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Testosterone; Weight Loss	2009
Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. Angiology, 2010, Volume: 61, Issue:4 Topics: Adipokines; Adult; Aged; Azetidines; Body Mass Index; Diet, Reducing; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2010
Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart (British Cardiac Society), 2011, Volume: 97, Issue:14 Topics: Anti-Obesity Agents; Canada; Carotid Arteries; Carotid Artery Diseases; Chi-Square Distribution; Disease Progression; Double-Blind Method; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Metabolic Syndrome; Obesity, Abdominal; Piperidines; Placebo Effect; Prospective Studies; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography; United States; Waist Circumference; Weight Loss	2011
Does rimonabant independently affect free fatty acid and glucose metabolism? The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:3 Topics: Adult; Aged; Behavior Therapy; Body Composition; Cannabinoid Receptor Antagonists; Diet, Reducing; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glucose; Glucose Clamp Technique; Humans; Insulin; Intra-Abdominal Fat; Life Style; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome; Weight Loss	2012
Fatty acid flux and oxidation are increased by rimonabant in obese women. Metabolism: clinical and experimental, 2012, Volume: 61, Issue:9 Topics: Adiponectin; Aged; Breath Tests; Cannabinoid Receptor Antagonists; Cholesterol; Diet, Reducing; Energy Intake; Energy Metabolism; Fatty Acids; Female; Humans; Insulin Resistance; Leptin; Lipolysis; Lipoproteins, VLDL; Middle Aged; Obesity; Oxidation-Reduction; Palmitic Acids; Piperidines; Pyrazoles; Rimonabant; Triglycerides; United Kingdom; Weight Loss	2012
CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans. International journal of obesity (2005), 2013, Volume: 37, Issue:5 Topics: Adult; Aged; Cannabinoid Receptor Antagonists; Double-Blind Method; Fatty Liver; Female; Finland; Humans; Liver; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Retrospective Studies; Rimonabant; Treatment Outcome; Weight Loss	2013
Efficacy of rimonabant in obese patients with binge eating disorder. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2013, Volume: 121, Issue:1 Topics: Adolescent; Adult; Aged; Binge-Eating Disorder; Cannabinoid Receptor Antagonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2013
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. The New England journal of medicine, 2005, Nov-17, Volume: 353, Issue:20 Topics: Adiponectin; Adult; Aged; Anti-Obesity Agents; Blood Glucose; Cannabinoid Receptor Antagonists; Cholesterol; Double-Blind Method; Dyslipidemias; Female; Humans; Insulin; Leptin; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Triglycerides; Weight Loss	2005
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA, 2006, Feb-15, Volume: 295, Issue:7 Topics: Adult; Aged; Anti-Obesity Agents; Blood Pressure; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Cholesterol, HDL; Diet, Reducing; Double-Blind Method; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Weight Loss	2006
[Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Revue medicale de Liege, 2007, Volume: 62, Issue:2 Topics: Anti-Obesity Agents; Bradykinin; Cannabinoids; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Glycated Hemoglobin; Heart; Humans; Insulin Resistance; Metabolic Syndrome; Obesity; Overweight; Piperidines; Placebos; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Triglycerides; Waist-Hip Ratio; Weight Loss	2007
Does a weight loss medicine make sense for obese type 2 diabetes? New information on endocannabinoid blockers. Current diabetes reports, 2007, Volume: 7, Issue:5 Topics: Appetite Depressants; Cannabinoids; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Obesity; Overweight; Patient Dropouts; Piperidines; Placebos; Pyrazoles; Rimonabant; Treatment Outcome; Weight Loss	2007
Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. Journal of hypertension, 2008, Volume: 26, Issue:2 Topics: Adult; Blood Pressure; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2008
A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. Clinical endocrinology, 2008, Volume: 69, Issue:6 Topics: Adult; Female; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Testosterone; Weight Loss	2008
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. European heart journal, 2008, Volume: 29, Issue:14 Topics: Adult; Anti-Obesity Agents; Blood Glucose; Body Mass Index; Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Cholesterol, HDL; Dose-Response Relationship, Drug; Epidemiologic Methods; Female; Humans; Insulin; Male; Metabolic Syndrome; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Treatment Outcome; Triglycerides; Weight Loss	2008

Other Studies

51 other study(ies) available for sr141716 and Weight Loss

Article	Year
Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antag Journal of medicinal chemistry, 2008, Sep-11, Volume: 51, Issue:17 Topics: Animals; Binding Sites; Hydrophobic and Hydrophilic Interactions; Mice; Mice, Obese; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship; Thiophenes; Weight Loss	2008
Novel cannabinoid receptor 1 inverse agonist CRB-913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet-induced obesity mouse model. Obesity (Silver Spring, Md.), 2023, Volume: 31, Issue:11 Topics: Animals; Body Weight; Diet; Drug Inverse Agonism; Incretins; Liraglutide; Mice; Obesity; Receptors, Cannabinoid; Rimonabant; Weight Loss	2023
A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:3 Topics: 3T3 Cells; Adipose Tissue; Animals; CHO Cells; Cricetulus; Cytokines; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Humans; Hypoglycemic Agents; Inflammasomes; Inflammation; Insulin Resistance; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; RAW 264.7 Cells; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Weight Loss	2019
Activation of NPRs and UCP1-independent pathway following CB1R antagonist treatment is associated with adipose tissue beiging in fat-fed male dogs. American journal of physiology. Endocrinology and metabolism, 2019, 09-01, Volume: 317, Issue:3 Topics: Adipose Tissue; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Diet, High-Fat; Dogs; Gene Expression; Inflammation; Insulin Resistance; Male; Organelle Biogenesis; Receptor, Cannabinoid, CB1; Receptors, Adrenergic, beta; Receptors, Atrial Natriuretic Factor; Rimonabant; Thermogenesis; Uncoupling Protein 1; Weight Loss	2019
Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats. Endocrinology, 2015, Volume: 156, Issue:4 Topics: Animals; Arachidonic Acids; Body Weight; Cannabinoid Receptor Antagonists; Endocannabinoids; Male; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss	2015
A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:5 Topics: Adipose Tissue, Brown; Adipose Tissue, White; Animals; Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Eating; Energy Metabolism; Fatty Liver; Ion Channels; Lipolysis; Male; Mice; Mice, Inbred C57BL; Mitochondrial Proteins; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Thermogenesis; Thiophenes; Uncoupling Protein 1; Weight Loss	2015
The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability. The international journal of neuropsychopharmacology, 2016, Volume: 19, Issue:12 Topics: Animals; Anxiety; Behavior, Addictive; Behavior, Animal; Cannabinoid Receptor Antagonists; Cues; Depression; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drug Inverse Agonism; Drug-Seeking Behavior; Male; Maze Learning; Mesencephalon; Motivation; Motor Activity; Piperidines; Pyrazoles; Rats, Long-Evans; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Swimming; Time Factors; Tobacco Use Cessation Devices; Tobacco Use Disorder; Weight Loss	2016
The element of surprise. Nature medicine, 2008, Volume: 14, Issue:7 Topics: Animals; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Clinical Trials as Topic; Delusions; Drug Administration Schedule; Humans; Lipogenesis; Mice; Mice, Knockout; Models, Biological; Nerve Endings; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Schizophrenia; Waist-Hip Ratio; Weight Loss	2008
Depression and weight loss: opposite outcome for surgery and rimonabant? Obesity reviews : an official journal of the International Association for the Study of Obesity, 2008, Volume: 9, Issue:5 Topics: Anti-Obesity Agents; Depression; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Safety; Treatment Outcome; Weight Loss	2008
[Pharmacological therapy of obesity]. Giornale italiano di cardiologia (2006), 2008, Volume: 9, Issue:4 Suppl 1 Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; Economics, Pharmaceutical; Humans; Lactones; Lipase; Meta-Analysis as Topic; Obesity; Orlistat; Piperidines; Practice Guidelines as Topic; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors; Time Factors; Weight Loss	2008
Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. American journal of physiology. Regulatory, integrative and comparative physiology, 2009, Volume: 296, Issue:4 Topics: Adiponectin; Animals; Anti-Obesity Agents; Dietary Fats; Disease Models, Animal; Eating; Glucose; Glucose Tolerance Test; Hyperinsulinism; Insulin; Insulin Resistance; Intra-Abdominal Fat; Lipids; Liver; Male; Mice; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Rimonabant; Subcutaneous Fat; Weight Loss	2009
Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet. American journal of physiology. Endocrinology and metabolism, 2009, Volume: 297, Issue:5 Topics: Adiponectin; Animals; Body Composition; Diet, High-Fat; Dietary Fats; DNA; DNA, Mitochondrial; Eating; Energy Metabolism; Glucose; Insulin Resistance; Liver Function Tests; Male; Mitochondria, Liver; Oxygen Consumption; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Triglycerides; Weight Loss	2009
TrkB agonist antibody dose-dependently raises blood pressure in mice with diet-induced obesity. American journal of hypertension, 2010, Volume: 23, Issue:7 Topics: Animals; Anti-Obesity Agents; Antibodies, Monoclonal; Blood Pressure; Body Weight; Brain-Derived Neurotrophic Factor; Diet; Dietary Fats; Hypertension; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Receptor, trkB; Rimonabant; Telemetry; Weight Loss	2010
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. European journal of pharmacology, 2010, Jun-25, Volume: 636, Issue:1-3 Topics: Adipose Tissue; Animals; Appetite; Biogenic Monoamines; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Cyclobutanes; Diet; Eating; Glucose Tolerance Test; Lipids; Male; Neurotransmitter Uptake Inhibitors; Obesity; Piperidines; Pyrazoles; Rats; Rimonabant; Time Factors; Weight Loss	2010
Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity. Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:3 Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Chemokine CCL2; Diet; Dietary Fats; Disease Models, Animal; Energy Intake; Inflammation; Liver; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Gain; Weight Loss	2011
Metformin may maintain weight loss in obese patients with dysglycaemia initially treated with rimonabant. Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:1 Topics: Humans; Hypoglycemic Agents; Metformin; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2011
[Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review]. Ugeskrift for laeger, 2011, Feb-21, Volume: 173, Issue:8 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cyclobutanes; Evidence-Based Medicine; Humans; Hypertension; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time Factors; Treatment Outcome; Weight Loss	2011
Leptin potentiates the anti-obesity effects of rimonabant. European journal of pharmacology, 2011, May-11, Volume: 658, Issue:2-3 Topics: Animals; Anti-Obesity Agents; Dose-Response Relationship, Drug; Drug Synergism; Leptin; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Recurrence; Rimonabant; Ventromedial Hypothalamic Nucleus; Weight Loss	2011
Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. International journal of clinical practice, 2011, Volume: 65, Issue:6 Topics: Adult; Biomarkers; Cannabinoid Receptor Modulators; Cholesterol; Fatty Liver; Female; Humans; Hypercholesterolemia; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity, Morbid; Piperidines; Pyrazoles; Retrospective Studies; Rimonabant; Safety-Based Drug Withdrawals; Triglycerides; Weight Loss	2011
Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice. Diabetologia, 2011, Volume: 54, Issue:12 Topics: Adipose Tissue, Brown; Animals; Body Composition; Diet, High-Fat; Energy Metabolism; Gluconeogenesis; Glucose; Glycogen; Insulin; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Muscle, Skeletal; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Thermogenesis; Weight Loss	2011
Effects of chronic oral rimonabant administration on energy budgets of diet-induced obese C57BL/6 mice. Obesity (Silver Spring, Md.), 2012, Volume: 20, Issue:5 Topics: Adipose Tissue; Administration, Oral; Animals; Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Eating; Energy Intake; Energy Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2012
Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice. International journal of obesity (2005), 2013, Volume: 37, Issue:2 Topics: Adipose Tissue, Brown; Adipose Tissue, White; Affect; Animals; Anti-Obesity Agents; Body Weight; Drug Therapy, Combination; Hypothalamic Hormones; Lipolysis; Male; Melanins; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Physical Conditioning, Animal; Piperidines; Pituitary Hormones; Pyrazoles; Rimonabant; Thermogenesis; Weight Loss	2013
Targeted inactivation of GPR26 leads to hyperphagia and adiposity by activating AMPK in the hypothalamus. PloS one, 2012, Volume: 7, Issue:7 Topics: Adiposity; AMP-Activated Protein Kinases; Animals; Diet; Dyslipidemias; Energy Metabolism; Enzyme Activation; Gene Silencing; Gene Targeting; Glucose Intolerance; Hyperinsulinism; Hyperphagia; Hypothalamus; Mice; Mice, Inbred C57BL; Obesity; Phosphorylation; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, G-Protein-Coupled; Rimonabant; Weight Loss	2012
Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant. Nutrition journal, 2012, Jul-23, Volume: 11 Topics: Adult; Aged; Blood Glucose; Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Diet; Dietary Carbohydrates; Dietary Fats; Energy Intake; Female; Humans; Male; Micronutrients; Middle Aged; Obesity; Piperidines; Pyrazoles; Regression Analysis; Rimonabant; Weight Loss	2012
Pharmacological modulation of the endocannabinoid signalling alters binge-type eating behaviour in female rats. British journal of pharmacology, 2013, Volume: 169, Issue:4 Topics: Animals; Behavior, Animal; Binge-Eating Disorder; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Drug Inverse Agonism; Drug Tolerance; Endocannabinoids; Energy Intake; Feeding Behavior; Female; Margarine; Piperidines; Pyrazoles; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Weight Loss	2013
Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss. Pharmacology, biochemistry, and behavior, 2004, Volume: 77, Issue:4 Topics: Animals; Dronabinol; Eating; Female; Maze Learning; Mice; Neurotransmitter Agents; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2004
[A new pill for metabolic syndrome. Successful control of lipids, kilos and cigarettes]. MMW Fortschritte der Medizin, 2004, Mar-25, Volume: 146, Issue:13 Topics: Cannabinoid Receptor Antagonists; Coronary Artery Disease; Dose-Response Relationship, Drug; Humans; Lipids; Metabolic Syndrome; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Smoking Cessation; United States; Weight Loss	2004
[Endocannabinoids receptor blocker lets tumble not only money. A drug against metabolic syndrome?]. MMW Fortschritte der Medizin, 2004, Nov-04, Volume: 146, Issue:45 Topics: Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Metabolic Syndrome; Piperidines; Placebos; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Time Factors; Weight Loss	2004
Another pill for weight reduction. Clinical cardiology, 2005, Volume: 28, Issue:2 Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2005
[Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management]. Deutsche medizinische Wochenschrift (1946), 2005, Mar-24, Volume: 130, Issue:12 Topics: Cannabinoid Receptor Modulators; Cardiovascular Diseases; Clinical Trials as Topic; Endocannabinoids; Humans; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Treatment Outcome; Weight Loss	2005
[In diabetes cannabinoid antagonist kills two birds with one stone]. MMW Fortschritte der Medizin, 2005, Sep-01, Volume: 147, Issue:35-36 Topics: Cannabinoid Receptor Antagonists; Cannabinoids; Controlled Clinical Trials as Topic; Diabetes Mellitus; Glycated Hemoglobin; Humans; Metabolic Syndrome; Piperidines; Placebos; Pyrazoles; Rimonabant; Time Factors; Weight Loss	2005
Appetite downer awaits approval. Nature, 2005, Sep-29, Volume: 437, Issue:7059 Topics: Appetite; Appetite Depressants; Clinical Trials as Topic; Diabetes Mellitus; Drug Approval; Drug Industry; Europe; France; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; United States; United States Food and Drug Administration; Weight Loss	2005
Pharmacotherapy for obesity--promise and uncertainty. The New England journal of medicine, 2005, Nov-17, Volume: 353, Issue:20 Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Cyclobutanes; Dyslipidemias; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2005
A new "wonder drug"? Diabetes forecast, 2005, Volume: 58, Issue:10 Topics: Diabetes Mellitus, Type 2; Humans; Piperidines; Pyrazoles; Rimonabant; United States; Weight Loss	2005
Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: a quasi abstinence approach. Brain research, 2005, Dec-20, Volume: 1066, Issue:1-2 Topics: Animals; Behavior, Animal; Cannabinoids; Cyclooxygenase Inhibitors; Diclofenac; Dronabinol; Male; Mice; Piperidines; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Rimonabant; Substance Withdrawal Syndrome; Weight Loss	2005
Rimonabant adds appetizing choice to slim obesity market. Nature medicine, 2006, Volume: 12, Issue:1 Topics: Appetite Depressants; Drug Evaluation; Drug Industry; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2006
[Reducing obesity]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:1 Pt 1 Topics: Adolescent; Adult; Appetite Depressants; Body Mass Index; Cardiovascular Diseases; Child; Cyclobutanes; Female; Humans; Life Style; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Risk Factors; Surveys and Questionnaires; Weight Loss	2006
Metabolic risk factors, drugs, and obesity. The New England journal of medicine, 2006, Mar-02, Volume: 354, Issue:9 Topics: Anti-Obesity Agents; Cardiovascular Diseases; Dyslipidemias; Glucose Intolerance; Humans; Obesity; Overweight; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2006
Coming soon: the lose-weight-stop-smoking pill that's good for your heart. Health news (Waltham, Mass.), 2006, Volume: 12, Issue:8 Topics: Cannabinoids; Cholesterol; Humans; Piperidines; Pyrazoles; Rimonabant; Smoking Prevention; Weight Loss	2006
Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation, 2006, Aug-29, Volume: 114, Issue:9 Topics: Anti-Obesity Agents; Humans; Life Style; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk; Weight Loss	2006
[Cardiac metabolic risk factors. CB1-blocker corrects three with one stroke]. MMW Fortschritte der Medizin, 2006, Aug-31, Volume: 148, Issue:35-36 Topics: Adolescent; Adult; Age Factors; Aged; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials, Phase III as Topic; Contraindications; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors; Time Factors; Triglycerides; Weight Loss	2006
Rimonabant in obese patients with type 2 diabetes. Lancet (London, England), 2007, Feb-17, Volume: 369, Issue:9561 Topics: Cannabinoid Receptor Antagonists; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; PPAR gamma; Pyrazoles; Rimonabant; Weight Loss	2007
Rimonabant in obese patients with type 2 diabetes. Lancet (London, England), 2007, Feb-17, Volume: 369, Issue:9561 Topics: Depression; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2007
[Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval]. MMW Fortschritte der Medizin, 2007, Jun-28, Volume: 149, Issue:27-28 Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Cannabinoids; Central Nervous System; Central Nervous System Diseases; Drug Approval; Germany; Humans; Mental Disorders; Metabolic Syndrome; Piperidines; Pyrazoles; Rimonabant; United States; United States Food and Drug Administration; Weight Loss	2007
[New drugs; rimonabant]. Nederlands tijdschrift voor geneeskunde, 2007, Nov-24, Volume: 151, Issue:47 Topics: Appetite Regulation; Cardiovascular Diseases; Depression; Diet, Reducing; Energy Intake; Humans; Lipids; Lipogenesis; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss	2007
[Antiobesity drugs--new limitations]. Revue medicale suisse, 2007, Nov-28, Volume: 3, Issue:135 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Depression; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Lactones; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Suicide; Weight Loss	2007
[Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects]. Lakartidningen, 2007, Dec-19, Volume: 104, Issue:51-52 Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Depression; Drug Approval; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Weight Loss	2007
Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats. Endocrinology, 2008, Volume: 149, Issue:5 Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Candy; Diet; Eating; Energy Metabolism; Fatty Acids, Nonesterified; Female; Liver Glycogen; Male; Photoperiod; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant; Time Factors; Weight Loss	2008
[The endocannabinoid system and treatment of obesity]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2008, Feb-28, Volume: 128, Issue:5 Topics: Animals; Anti-Obesity Agents; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss	2008
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes. Current atherosclerosis reports, 2008, Volume: 10, Issue:2 Topics: Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies; Humans; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Life Style; Myocardial Infarction; Obesity; Pioglitazone; Piperidines; Platelet Aggregation Inhibitors; Prediabetic State; Pyrazoles; Ramipril; Rimonabant; Risk Assessment; Thiazolidinediones; Triglycerides; Weight Loss	2008
Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life sciences, 1998, Volume: 63, Issue:8 Topics: Animals; Appetite; Appetite Depressants; Cannabinoids; Drinking; Drug Tolerance; Eating; Kinetics; Male; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rimonabant; Weight Loss	1998